50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention

Key Takeaways Explain This Topic AI

Typical angina pectoris satisfies all three Diamond-Forrester criteria: substernal chest discomfort of characteristic quality and duration, provocation by physical exertion or emotional stress, and prompt relief within 5 minutes by rest or sublingual nitroglycerin; atypical angina satisfies two criteria, whereas non-cardiac chest pain satisfies zero or one.

Non-invasive diagnostic testing is dictated by pre-test probability and baseline electrocardiogram: exercise treadmill ECG testing is first-line for patients with interpretable baseline ECGs capable of >=5 METs of exercise, stress echocardiography or myocardial perfusion scintigraphy (SPECT/PET) is required for baseline ECG abnormalities (LBBB, ST depression >1 mm, paced rhythms) or physical disability, and Coronary CT Angiography (CCTA) provides superior negative predictive value (>98%) in low-to-intermediate risk cohorts.

Antianginal medical therapy prioritizes beta-blockers as first-line agents titrated to a resting heart rate of 55-60 bpm; long-acting nitrates (isosorbide mononitrate) require a mandatory daily 10-14 hour nitrate-free interval to avoid vascular tolerance and are strictly contraindicated with phosphodiesterase-5 inhibitors due to fatal refractory hypotension.

Post-myocardial infarction secondary prevention relies on the 'Fantastic Four' pharmacotherapy bundle: 1) Dual Antiplatelet Therapy (aspirin 81 mg indefinitely plus ticagrelor or prasugrel for >=12 months), 2) High-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 20-40 mg targeting LDL-C <55-70 mg/dL with >=50% reduction), 3) Evidence-based beta-blockers (for at least 1-3 years if LVEF normal, indefinitely if LVEF <=40%), and 4) ACE inhibitors or ARBs (indicated for LVEF <=40%, hypertension, diabetes, or CKD).

Post-MI survivors require early outpatient cardiac rehabilitation referral (Class 1A recommendation, reducing all-cause mortality by ~25%) and annual inactivated influenza vaccination (reducing secondary cardiovascular events by 18-28%).

Last updated: September 2026

Pathophysiology & Clinical Presentation of Chronic Coronary Disease

Chronic Coronary Disease (CCD), formerly termed Stable Ischemic Heart Disease (SIHD), is characterized by transient, reversible myocardial ischemia resulting from an imbalance between myocardial oxygen supply and myocardial oxygen demand ( M V O 2 MVO_2 M V O 2 ) .

Determinants of Myocardial Oxygen Dynamics

Myocardial Oxygen Demand ( M V O 2 MVO_2 M V O 2 ) : Governed by three primary hemodynamic factors:

Heart Rate : Tachycardia increases metabolic cycles per minute and shortens diastolic perfusion time;
Myocardial Contractility (Inotropic State) : Increased velocity and force of myocardial fiber shortening;

Systolic Ventricular Wall Tension : Defined by Laplace's law ( W a l l T e n s i o n = P r e s s u r e × R a d i u s 2 × W a l l T h i c k n e s s Wall\ Tension = \frac{Pressure \times Radius}{2 \times Wall\ Thickness} Wa ll T e n s i o n = 2 × Wa ll T hi c kn ess P ress u re × R a d i u s ); driven by left ventricular afterload (systemic blood pressure) and preload (end-diastolic volume).

Myocardial Oxygen Supply : Oxygen extraction by cardiac myocytes is near-maximal (~75%) even at rest. Consequently, any increase in oxygen demand must be met by an increase in coronary blood flow . Coronary perfusion occurs almost exclusively during diastole , because during systole, contracting ventricular myocardium compresses intramural coronary arterioles.

Critical Stenosis Thresholds :

In healthy coronary arteries, autoregulatory arteriolar vasodilation can increase coronary blood flow up to four- to five-fold during exertion ( coronary flow reserve ).

When an atherosclerotic plaque narrows the luminal cross-sectional area by >=70% (or >=50% for the left main coronary artery ), maximal downstream arteriolar vasodilation is exhausted at rest. Any exertional increase in M V O 2 MVO_2 M V O 2 induces transmural myocardial ischemia, precipitating angina.

At luminal stenosis >=90% , resting blood flow is impaired, predisposing to ischemia even at rest.

Clinical Classification of Chest Discomfort: Diamond-Forrester Criteria

The Diamond-Forrester clinical classification remains the foundational tool for stratifying chest discomfort and estimating pre-test probability: DIAMOND-FORRESTER CLASSIFICATION OF CHEST PAIN

Classification Definition & Diagnostic Criteria
═════════════════════════════════════════════════════════════════════════════════════════

Typical Angina Meets ALL THREE of the following cardinal clinical criteria:

(Definite) 1. Substernal chest discomfort with characteristic quality (pressure,
squeezing, heaviness, tightness) and duration (2 to 10 minutes);
2. Provoked by physical exertion or emotional / psychological stress;

3. Promptly relieved by rest OR sublingual nitroglycerin within 5 min.

Atypical Angina Meets EXACTLY TWO of the three cardinal criteria above.

(Probable) (Frequently encountered in women, elderly patients, and diabetics).

Non-Cardiac Pain Meets ZERO or ONLY ONE of the three cardinal criteria above.

(Suggests musculoskeletal, gastrointestinal, or pulmonary etiologies).

═════════════════════════════════════════════════════════════════════════════════════════

Anginal Equivalents : Vulnerable demographic cohorts—particularly women, older adults (>=75 years), and individuals with longstanding diabetes mellitus —frequently present without classic substernal pressure. Instead, they manifest "anginal equivalents": new or worsening exertional dyspnea , unexplained extreme fatigue, diaphoresis, epigastric burning, nausea, or presyncope. In diabetics, autonomic cardiac neuropathy blunts visceral nociceptive transmission, permitting silent myocardial ischemia and delayed presentation.

Diagnostic Testing Cascade: Pre-Test Probability & Modality Selection

The diagnostic evaluation of suspected chronic coronary disease begins with calculating the patient's pre-test probability (PTP) based on age, biological sex, and chest pain classification (typical, atypical, or non-cardiac). Patients with very low PTP (<5%) generally require no cardiac testing, whereas those with intermediate (5% to 85%) or high (>85%) PTP require non-invasive functional or anatomical imaging. NON-INVASIVE DIAGNOSTIC TESTING MODALITIES

Modality Key Patient Indications Major Contraindications / Limitations

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Exercise Treadmill Able to exercise (>=5 METs, achieve Uninterpretable baseline resting ECG:

ECG Testing (TMT) >=85% max predicted HR); normal baseline LBBB, paced rhythm, ST depression >1 mm,

resting ECG; intermediate PTP WPW pre-excitation, digitalis use.

Exercise Stress Normal or abnormal resting ECG; able to Poor acoustic windows (severe COPD, severe

Echocardiography exercise; assesses regional wall motion obesity); cannot exercise.

Pharmacologic Stress Unable to exercise (amputee, severe OA, Severe active reactive airway disease / asthma
Scintigraphy (SPECT/ frailty); abnormal baseline ECG; assesses (contraindicates adenosine/regadenoson);

PET Perfusion) myocardial perfusion & viability caffeine/theophylline within 12-24 hours.

Dobutamine Stress Unable to exercise; contraindication to Severe ventricular arrhythmias, severe

Echocardiography vasodilators (severe reactive airway disease) hypertension (>220/120 mmHg), recent ACS.

Coronary CT Low-to-intermediate PTP; high negative Severe extensive coronary calcification
Angiography (CCTA) predictive value (>98%); assesses anatomical (Agatston calcium score >1000); renal failure

plaque burden and luminal stenosis (contrast); irregular heart rhythms (atrial fib).

Non-Invasive Testing Modality Selection

Exercise Treadmill ECG Testing (Standard Bruce Protocol) :

Preferred initial test in patients who are fully capable of physical exercise (can achieve >=5 metabolic equivalents [METs], such as climbing two flights of stairs or walking briskly up a hill) and possess an interpretable baseline resting ECG .

Diagnostic Positivity : Horizontal or downsloping ST-segment depression of >=1.0 mm (0.1 mV) measured 80 milliseconds past the J-point during or immediately following exercise.

The Uninterpretable ECG Rule : Exercise treadmill ECG testing without imaging is completely non-diagnostic if the baseline ECG displays: Left Bundle Branch Block (LBBB) , ventricular paced rhythm, pre-excitation (Wolff-Parkinson-White syndrome), baseline ST-segment depression >1.0 mm (e.g., from severe LVH with strain), or digoxin effect. These patients must undergo imaging (stress echocardiography or nuclear perfusion scintigraphy).

Pharmacologic Vasodilator Stress Testing (Regadenoson, Adenosine, Dipyridamole) :

Indicated in patients physically unable to exercise.

Mechanism : Selective coronary arteriolar vasodilators (adenosine A2A receptor agonists) produce maximal hyperemia in healthy coronary arteries, increasing blood flow four- to five-fold. Diseased coronary arteries with fixed stenoses cannot vasodilate further. This creates a relative disparity in blood flow ("coronary steal"), visualized on SPECT or PET myocardial perfusion imaging as a reversible perfusion defect.

Contraindications & Precautions : Strictly contraindicated in patients with active, severe bronchospastic airway disease (asthma with wheezing) because adenosine A2B/A3 receptor activation can trigger fatal bronchospasm. Patients must abstain from caffeine, theophylline, and methylxanthines for 12 to 24 hours prior to testing, as these compounds competitively antagonize adenosine receptors and cause false-negative scans.

Coronary Computed Tomographic Angiography (CCTA) :

CCTA provides non-invasive anatomical visualization of the coronary lumen and vessel wall, boasting an exceptional negative predictive value exceeding 98% .

Endorsed by ACC/AHA guidelines as an outstanding first-line test for low-to-intermediate risk patients presenting with stable chest pain: a normal CCTA reliably excludes obstructive coronary disease and portends an excellent long-term prognosis, safely obviating downstream invasive testing.

Medical Antianginal Therapy & The Nitrate Tolerance Phenomenon

Medical management of chronic stable angina aims to alleviate symptoms, prevent exercise-induced ischemia, and improve quality of life. Guidelines emphasize a stepwise pharmacologic approach: STEPWISE MEDICAL ANTIANGINAL PHARMACOTHERAPY

Therapeutic Line Drug Class & Specific Agents Hemodynamic Effects & Mechanism

First-Line Antianginal Beta-Blockers: Decreases HR, contractility, and SBP;
Metoprolol succinate, Carvedilol, Atenolol lowers MVO2; lengthens diastolic filling time;

(Titrate to resting HR 55 to 60 bpm) mortality benefit in post-MI and HFrEF.

Second-Line Add-On Dihydropyridine CCBs: Arteriolar vasodilation reduces afterload;

or Alternative Amlodipine (5-10 mg), Felodipine coronary vasodilation; synergistic with BB.

Non-Dihydropyridine CCBs: Lowers HR and contractility; alternative if BB

Diltiazem, Verapamil contraindicated; AVOID in HFrEF.

Long-Acting Nitrates: Venodilation reduces preload (LVEDP and wall

Isosorbide mononitrate ER (30-120 mg) stress); requires 10-14h daily nitrate-free interval.

Third-Line / Ranolazine Selective late sodium current (INa) inhibitor;
Refractory Angina (500 to 1,000 mg twice daily) reduces intracellular Ca2+ overload and diastolic

wall tension; NO EFFECT on HR or BP.

Pharmacologic Mechanics & Safety Mandates

First-Line Beta-Blockade : Beta-blockers are the undisputed first-line antianginal agents in patients without contraindications. By competitively inhibiting cardiac beta-1 adrenergic receptors, they reduce resting and exercise-induced heart rate and myocardial contractility, directly diminishing M V O 2 MVO_2 M V O 2 . The clinical dosing target is a resting heart rate of 55 to 60 beats per minute , with an exercise heart rate not exceeding 100 beats per minute.

Long-Acting Nitrates & The Nitrate-Free Interval :

Nitrates undergo intracellular metabolic bioactivation via mitochondrial aldehyde dehydrogenase (ALDH-2) to release nitric oxide (NO) , stimulating soluble guanylate cyclase and generating cyclic guanosine monophosphate (cGMP). The resulting smooth muscle relaxation predominantly dilates large capacitance systemic veins, reducing venous return (preload), left ventricular end-diastolic pressure, and intramyocardial wall tension.

The Nitrate Tolerance Phenomenon : Continuous round-the-clock exposure to nitrates leads to rapid development of tolerance (tachyphylaxis) within 24 to 48 hours, rendering the drug completely ineffective. This is driven by depletion of intracellular sulfhydryl donors, uncoupling of endothelial nitric oxide synthase, and neurohormonal reflex activation.

The Mandate : To preserve antianginal efficacy, all long-acting nitrate regimens (oral isosorbide mononitrate or transdermal nitroglycerin patches) must incorporate a daily 10- to 14-hour nitrate-free interval (e.g., administering once-daily extended-release isosorbide mononitrate in the morning, or removing transdermal patches at bedtime).

Caution

THE ABSOLUTE CONTRAINDICATION: NITRATES & PDE-5 INHIBITORS Concurrent administration of any nitrate formulation (sublingual nitroglycerin, long-acting isosorbide mononitrate/dinitrate) with phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, vardenafil, tadalafil) is STRICTLY CONTRAINDICATED .

Nitrates stimulate cGMP production, while PDE-5 inhibitors block cGMP degradation. Co-administration causes massive, unchecked cGMP accumulation in vascular smooth muscle, triggering catastrophic, refractory vasodilation, profound hypotension, coronary hypoperfusion, and fatal cardiac arrest .

Nitrates must be withheld for at least 24 hours after the last dose of sildenafil or vardenafil , and for at least 48 hours after the last dose of tadalafil (due to its extended 17.5-hour half-life).

Ranolazine Mechanics :

Ranolazine selectively inhibits the late inward sodium current ( I N a I_{Na} I N a ) during myocardial repolarization. In ischemic myocytes, excess late sodium entry leads to reverse operation of the sodium-calcium exchanger ( N C X NCX NCX ), producing pathological intracellular calcium overload , impaired diastolic relaxation, and microvascular compression.

By blocking this sodium influx, ranolazine decreases intracellular calcium, improves diastolic compliance, and enhances subendocardial perfusion WITHOUT affecting heart rate, blood pressure, or inotropy . It is particularly valuable in patients limited by bradycardia or borderline hypotension. It causes dose-dependent prolongation of the QTc interval, necessitating baseline and follow-up ECG monitoring.

Post-MI / Post-PCI Secondary Prevention: The "Fantastic Four" Bundle

Following acute myocardial infarction (STEMI or NSTEMI) and percutaneous coronary intervention (PCI) with drug-eluting stents (DES), long-term management is focused on aggressive secondary prevention to prevent stent thrombosis, recurrent infarction, adverse ventricular remodeling, and cardiovascular death. Guideline consensus mandates the immediate initiation of the "Fantastic Four" secondary prevention bundle : THE POST-MI SECONDARY PREVENTION "FANTASTIC FOUR"

Pillar Specific Guideline Regimen Mechanisms & Clinical Targets
═════════════════════════════════════════════════════════════════════════════════════════════════════════════
1. Dual Antiplatelet Aspirin 81 mg daily INDEFINITELY Inhibits COX-1 thromboxane A2;
Therapy (DAPT) PLUS Ticagrelor 90 mg BID (or Prasugrel Inhibits P2Y12 ADP platelet receptor;

10 mg daily) for a MINIMUM OF 12 MONTHS prevents acute stent thrombosis.

2. High-Intensity Atorvastatin 80 mg daily (or 40 mg) Plaque stabilization, anti-inflammatory;
Statin Therapy OR Rosuvastatin 20 to 40 mg daily Target LDL-C reduction >=50% AND

INDEFINITELY for all post-MI patients absolute LDL-C < 55 to 70 mg/dL.

3. Beta-Blocker Evidence-based agents: Reduces ventricular arrhythmogenesis & MVO2;
Therapy Carvedilol, Metoprolol succinate, Bisoprolol Minimum 1 to 3 years if LVEF normal;

titrated to resting HR 55-60 bpm INDEFINITELY if LVEF <= 40%.

4. ACE Inhibitor Lisinopril, Ramipril, or Enalapril Inhibits RAAS-mediated adverse ventricular
or ARB (ARBs: Losartan, Valsartan if ACEi intolerant) remodeling; indicated in LVEF <= 40%,

hypertension, diabetes mellitus, or CKD.

═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Clinical Nuances of Post-MI Pharmacotherapy

Dual Antiplatelet Therapy (DAPT) :

P2Y12 Inhibitor Selection : In the post-ACS/PCI setting, Ticagrelor (90 mg twice daily) or Prasugrel (10 mg daily) is strongly preferred over Clopidogrel (75 mg daily) based on the landmark PLATO and TRITON-TIMI 38 trials, which demonstrated significant reductions in ischemic death, recurrent MI, and stent thrombosis.

Prasugrel Contraindications : Prasugrel is STRICTLY CONTRAINDICATED in patients with a history of stroke or transient ischemic attack (TIA) due to a significant increase in fatal intracranial hemorrhage. It is also generally avoided in patients aged >=75 years or weighing <60 kg.

Ticagrelor Nuances : Ticagrelor causes a reversible, non-bronchospastic dyspnea in 10% to 15% of patients (mediated by inhibition of cellular adenosine reuptake) that typically resolves over several weeks without causing heart failure or pulmonary injury. Maintenance aspirin doses combined with ticagrelor must not exceed 81 mg daily , as higher aspirin doses (>100 mg) significantly attenuate ticagrelor's clinical efficacy.

Duration : Minimum duration of DAPT is 12 months post-ACS regardless of stent type, after which P2Y12 therapy is discontinued and aspirin 81 mg daily is continued indefinitely.

High-Intensity Statin & Non-Statin Escalation :

All post-MI patients require immediate, high-intensity statin therapy regardless of their baseline LDL-C level.

Targets : Achieve >=50% reduction in baseline LDL-C AND achieve an absolute LDL-C <70 mg/dL (with modern ACC/AHA and European guidelines advocating an even stricter target of <55 mg/dL for very high-risk ASCVD).

Non-Statin Add-On Therapy :

Recheck fasting lipid panel 4 to 12 weeks post-MI.

If LDL-C remains >=70 mg/dL despite maximally tolerated high-intensity statin therapy, add Ezetimibe 10 mg daily (supported by the IMPROVE-IT trial, showing significant further reduction in recurrent cardiovascular events).

If LDL-C remains >=70 mg/dL on maximally tolerated statin plus ezetimibe in very high-risk patients, add a PCSK9 inhibitor (evolocumab or alirocumab subcutaneously every 2-4 weeks; supported by the FOURIER and ODYSSEY Outcomes trials).

Beta-Blocker Duration :

Post-MI patients with reduced LV systolic function (LVEF <=40%) must continue an evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol) indefinitely to prevent sudden cardiac death and heart failure progression.

In post-MI patients with preserved LV function (LVEF >50%) who have undergone successful revascularization and lack persistent angina or arrhythmias, current guidelines recommend continuing beta-blocker therapy for at least 1 to 3 years , after which reassessment and potential de-escalation may be considered.

Critical Post-MI Interventions: Cardiac Rehab & Vaccinations

Comprehensive Outpatient Cardiac Rehabilitation :

A structured, multidisciplinary outpatient program comprising medically monitored aerobic exercise training, cardiovascular risk factor reduction, nutritional education, and psychosocial counseling.

Class 1A Guideline Recommendation : Participation in cardiac rehabilitation confers a 25% relative reduction in all-cause mortality , lowers recurrent hospitalizations, and improves functional capacity. Every post-MI patient must be formally referred prior to hospital discharge.

Preventive Immunizations :

Annual Inactivated Influenza Vaccination : Acute influenza infection triggers severe systemic inflammation, sympathetic surge, and prothrombotic cascades that precipitate acute coronary plaque rupture. Landmark randomized clinical trials (such as the IAMI trial) demonstrate that receiving an influenza vaccine immediately post-MI reduces all-cause mortality and secondary cardiovascular composite events by 18% to 28% .

Pneumococcal Vaccination : Post-MI patients should receive pneumococcal immunization (PCV20 alone or PCV15 followed by PPSV23) to prevent bacteremic pneumococcal pneumonia.